Trials / Unknown
UnknownNCT01821482
A Study of DC-CIK to Treat Hepatocellular Carcinoma
A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Guangxi Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of Dendritic and Cytokine-induced Killer Cells (DC-CIK) for hepatocellular carcinoma (HCC).
Detailed description
About 60 patients with HCC, who had received complete resection or TACE and got Complete remission (CR) or partial response (PR), will be randomly divided into group A (receive DC-CIK treatment) or group B (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks). Patients in group B will have no anti-tumor therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dendritic and Cytokine-induced Killer Cells |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2013-04-01
- Last updated
- 2013-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01821482. Inclusion in this directory is not an endorsement.